Parkinson’s disease
R&D/ Views & Analysis/ Views and analysis
For neurological disease, solving measurement is the first and biggest hurdle to re-imagining treatment
Jonah Comstock
Alzheimer's disease, Biomarkers, digital technology, Parkinson's disease
0 Comment
Biogen bolsters pipeline again with Alectos deal
Phil Taylor
Alectos Therapeutics, Biogen, neurology, Parkinson's disease, partnering
0 Comment
AbbVie files continuous Parkinson’s therapy ABBV-951 in US
Phil Taylor
ABBV-951, AbbVie, drug delivery, neurology, Parkinson's disease
0 Comment
PreciseDx AI diagnostic can detect early-stage Parkinson’s
Phil Taylor
diagnostic, digital, digital health, neurology, Parkinson's disease, PreciseDx
0 Comment
BioArctic left in the cold as AbbVie abandons Parkinson’s pact
Phil Taylor
AbbVie, BioArctic, neurology, Parkinson's disease, partnering
0 Comment
After ph2 win, Cerevance preps pivotal trials of novel Parkinson’s drug
Phil Taylor
central nervous system, Cerevance, neurodegenerative disease, Parkinson's disease
0 Comment
MindMaze raises $105m to seek out new neurological DTx
Phil Taylor
Alzheimer's disease, digital, digital health, digital therapeutics, financing, MindMaze, neurology, Parkinson's disease, stroke
0 Comment
Sanofi places $75m bet with ABL on popular Parkinson’s drug target
Phil Taylor
ABL Bio, bispecific antibody, Parkinson's disease, partnering, Sanofi
0 Comment